X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217917
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217917
https://www.fiercebiotech.com/biotech/fda-nixes-eua-ambitions-eigers-covid-treatment-proposes-full-approval-pathway-instead
https://endpts.com/unpersuaded-by-the-data-fda-rejects-cheap-generic-ssri-as-a-covid-19-drug/
https://trialsitenews.com/fluvoxamines-moment-how-a-controversial-off-patent-psychiatric-treatment-went-legit/
https://trialsitenews.com/university-of-minnesota-pi-submits-eua-application-to-fda-for-fluvoxamine/
https://endpts.com/cheap-ssri-drug-proves-successful-in-reducing-covid-related-hospitalization-times-large-study-finds/
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/antidepressant-fluvoxamine-may-reduce-risk-of-covid-19-hospitalisation-lancet-study/articleshow/87330536.cms
https://endpts.com/covid-19-roundup-eua-for-booster-mrna-shot-imminent-reports-ema-probes-skin-kidney-reactions-to-vaccine/
https://www.prnewswire.com/news-releases/fluvoxamine-data-unveiled-as-promising-early-treatment-in-patients-with-mild-covid-19-301146870.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212182
https://www.clinicaltrialsarena.com/news/us-fluvoxamine-covid-19-trial/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212182
Market Place
Share 
